MOTS-c

MOTS-c is a naturally occurring mitochondrial-derived peptide being studied, mostly in animals, for effects on metabolism and exercise capacity. As an injected research product it is not approved for human therapeutic use in Australia and remains experimental.

What it is

MOTS-c is a small peptide encoded within the mitochondrial genome. It occurs naturally in the human body, where it appears to act as a signalling molecule involved in metabolism. As a naturally circulating peptide it is a legitimate subject of study. However, MOTS-c sold as an injectable "research peptide" for human use is a different matter: those products are unapproved research chemicals, not registered medicines, and are not manufactured to pharmaceutical standards for therapeutic use.

How it works

MOTS-c is described as a mitochondrial-derived peptide with "exercise-mimetic" activity. In laboratory studies it influences cellular energy sensing — notably the AMPK pathway — and has been reported to stimulate glucose utilisation, promote fat oxidation, improve insulin sensitivity and reduce inflammation. Levels appear to rise with exercise and tend to be lower in obesity, diabetes and ageing. The mechanistic detail is largely from animal and cell studies rather than controlled human therapeutic trials.

What the evidence says

Most robust evidence is preclinical. In mice, MOTS-c improves insulin sensitivity and protects against diet-induced metabolic problems. Human data is far more limited. Observational human work shows natural MOTS-c levels rise after exercise, but this measures the body's own peptide, not the effect of injecting it. A MOTS-c analogue (CB4211) completed an early Phase 1 trial suggesting it was generally tolerated over short dosing, though injection-site reactions were common. As of 2026 there are no completed late-stage trials establishing that administered MOTS-c is effective, and it is not approved for any human therapeutic use.

Legal & regulatory status in Australia

MOTS-c is not on the ARTG and is not TGA-approved for human therapeutic use. Injectable peptides supplied for human use generally fall under Schedule 4 (Prescription Only), meaning they cannot lawfully be supplied for human use without a valid prescription and appropriate approval. Products marketed online as "research only" MOTS-c are not approved medicines, and the TGA has taken enforcement action against unlawful peptide supply. Assume MOTS-c injectables are not lawfully available for general human use in Australia.

Risks & considerations

Administered MOTS-c has very limited human safety data, so its side-effect profile, safe dosing and long-term effects are not well characterised; the closest human data noted frequent injection-site reactions. As an injectable it carries the usual injection risks plus the major problem that research-grade peptides are commonly mislabelled, underdosed, impure or contaminated. Sterility cannot be assumed, and there is no data on interactions.

What to ask a doctor

• Are there approved, evidence-based options for my metabolic or fitness goals?
• What are the specific risks of an unapproved injectable peptide with little human data?
• Could it interact with my medications or health conditions?
• What does the lack of TGA approval mean for safety and legality?
• What proven lifestyle or medical steps would you suggest instead?

FAQ

Q: Is MOTS-c approved for human use? A: No. While MOTS-c occurs naturally in the body, MOTS-c products administered to humans are not TGA-approved and remain experimental, with no completed late-stage human trials proving benefit. Q: Is MOTS-c the same as exercise? A: No. It is called an "exercise mimetic" because it shares some metabolic signalling with exercise in lab studies, but there is no human evidence it reproduces exercise's overall benefits when administered. Q: Are "research only" MOTS-c products safe to inject? A: Their safety is not established. Research-grade peptides can be impure, non-sterile or mislabelled, and human data is minimal.